Deletion of striatal adenosine A2A receptor spares latent inhibition and prepulse inhibition but impairs active avoidance learning

Behavioural Brain Research

Volumn 242, Issue 1, 2013, Pages 54-61

  Singer, Philipp ^a,b   Wei, Catherine J ^c   Chen, Jiang Fan ^c   Boison, Detlev ^b   Yee, Benjamin K ^a,b  

^a ETH ZURICH   (Switzerland)

^b LEGACY RESEARCH   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

A2A receptor; Adenosine; Latent inhibition; Prepulse inhibition; Schizophrenia

Indexed keywords

ADENOSINE A2A RECEPTOR; DOPAMINE; GLUTAMIC ACID;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; AVERSIVE BEHAVIOR; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; KNOCKOUT MOUSE; LATENT INHIBITION; LOCOMOTION; MALE; MOUSE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; SELECTIVE ATTENTION; SENSORY GATING; STARTLE REFLEX; TASTE AVERSION;

ANALYSIS OF VARIANCE; ANIMALS; AVOIDANCE LEARNING; CONDITIONING (PSYCHOLOGY); CORPUS STRIATUM; HOMEODOMAIN PROTEINS; INHIBITION (PSYCHOLOGY); LEARNING DISORDERS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOTOR ACTIVITY; PSYCHOACOUSTICS; RECEPTOR, ADENOSINE A2A; REFLEX, ACOUSTIC; SENSORY GATING; TASTE;

EID: 84872369392     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.12.024     Document Type: Article

References (72)

1. Altar C.A., Wasley A.M., Neale R.F., Stone G.A. Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain. Brain Research Bulletin 1986, 16:517-525.
2. Borison R.L., Hitri A., Blowers A.J., Diamond B. Antipsychotic drug action: clinical, biochemical and pharmacological evidence for site specificity of action. Clinical Neuropharmacology 1983, 76:137-150.
3. Ögren S.O., Hall H., Köhler C., Magnusson O., SjöstrandS.E. The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine mediated motor functions. Psychopharmacology 1986, 90:287-294.
4. Seeman P., Schwarz J., Chen J.F., Szechtman H., Perreault M., McKnight G.S., et al. Psychosis pathways converge via D2high dopamine receptors. Synapse 2006, 60:319-346.
5. Boison D., Singer P., Shen H.Y., Feldon J., Yee B.K. Adenosine hypothesis of schizophrenia - opportunities for pharmacotherapy. Neuropharmacology 2012, 62:1527-1543.
6. Lara D.R., Dall'Igna O.P., Ghisolfi E.S., Brunstein M.G. Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2006, 30:617-629.
7. Lara D.R., Souza D.O. Schizophrenia: apurinergic hypothesis. Medical Hypotheses 2000, 54:157-166.
8. Fredholm B.B., Chen J.F., Cunha R.A., Svenningsson P., Vaugeois J.M. Adenosine and brain function. International Review of Neurobiology 2005, 63:191-270.
9. Jacobson K.A., Gao Z.G. Adenosine receptors as therapeutic targets. Nature Reviews Drug Discovery 2006, 5:247-264.
10. Rosin D.L., Robeva A., Woodard R.L., Guyenet P.G., Linden J. Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system. Journal of Comparative Neurology 1998, 40:163-186.
11. Schiffmann S.N., Jacobs O., Vanderhaeghen J.-J. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. Journal of Neurochemistry 1991, 57:1062-1067.
12. Ferré S., O'Connor W.T., Snaprud P., Ungerstedt U., Fuxe K. Antagonistic interaction between adenosine A2A receptors and dopamine D2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia. Neuroscience 1994, 63:765-773.
13. Fuxe K., Ferré S., Zoli M., Agnati L.F. Integrated events in central dopamine transmission as analyzed at multiple levels. Evidence for intramembrane adenosine A2A/dopamine D2 and adenosine A1/dopamine D1 receptor interactions in the basal ganglia. Brain Research Reviews 1998, 26:258-273.
14. Fuxe K., Ferré S., Genedani S., Franco R., Agnati L.F. Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function. Physiology and Behavior 2007, 92:210-217.
15. Ferré S. Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacology 1997, 133:107-120.
16. Fuxe K., Marcellino D., Borroto-Escuela D.O., Guescini M., Fernández-Dueñas V., Tanganelli S., et al. Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neuroscience and Therapeutics 2010, 16:18-42.
17. Deckert J., Brenner M., Durany N., Zochling R., Paulus W., Ransmayr G., et al. Up-regulation of striatal adenosine A(2A) receptors in schizophrenia. Neuroreport 2003, 14:313-316.
18. Kurumaji A., Toru M. An increase in [3H] CGS21680 binding in the striatum of postmortem brains of chronic schizophrenics. Brain Research 1998, 808:320-323.
19. Shen H.Y., Coelho J.E., Ohtsuka N., Canas P.M., Day Y.J., Huang Q.Y., et al. A critical role of the adenosine A2A receptor in extrastriatal neurons in modulating psychomotor activity as revealed by opposite phenotypes of striatum and forebrain A2A receptor knock-outs. Journal of Neuroscience 2008, 28:2970-2975.
20. Lubow R.E., Moore A.U. Latent inhibition: the effect of non-reinforced preexposure to the conditional stimulus. Journal of Comparative and Physiological Psychology 1959, 66:688-694.
21. Lubow R.E. Latent inhibition and Conditioned Attentional Theory 1989, Cambridge University Press, Cambridge.
22. Mackintosh N.J. Stimulus selection: learning to ignore stimuli that predict no change in reinforcement. Constraints on Learning 1973, 75-96. Academic Press, London. R.A. Hinde, J. Stevenson-Hinde (Eds.).
23. Wagner A.R. Expectancies and the priming of STM. Cognitive Processes in Animal Behavior 1978, 177-209. Lawrence Erlbaum, Hillsdale NJ. T.J. Tighe, H. Fowler, W.K. Honig (Eds.).
24. Braff D.L., Geyer M.A., Swerdlow N.R. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology 2001, 156:234-258.
25. Baruch I., Hemsley D.R., Gray J.A. Differential performance of acute and chronic schizophrenics in a latent inhibition task. Journal of Nervous and Mental Disease 1988, 176:598-606.
26. Gray N.S., Pilowsky L.S., Gray J.A., Kerwin R.W. Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET. Schizophrenia Research 1995, 17:95-107.
27. Graham F.K. The more or less startling effects of weak prestimulation. Psychophysiology 1975, 12:238-248.
28. Geyer M.A., Krebs-Thomson K., Braff D.L., Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 2001, 156:117-154.
29. Lipska B.K., Swerdlow N.R., Geyer M.A., Jaskiw G.E., Braff D.L., Weinberger D.R. Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology 1995, 122:35-43.
30. Meyer U., Feldon J., Schedlowski M., Yee B.K. Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia. Neuroscience and Biobehavioral Reviews 2005, 29:913-947.
31. Moser P.C., Hitchocock J.M., Liste S., Moran P.M. The pharmacology of latent inhibition as an animal model of schizophrenia. Brain Research Reviews 2000, 33:275-307.
32. Powell S.B., Zhou X., Geyer M.A. Prepulse inhibition and genetic mouse models of schizophrenia. Behavioural Brain Research 2009, 204:282-294.
33. Weiner I., Arad M. Using the pharmacology of latent inhibition to model domains of pathology in schizophrenia and their treatment. Behavioural Brain Research 2009, 204:369-386.
34. Weiner I. The " two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology 2003, 69:257-297.
35. Swerdlow N.R., Geyer M.A., Braff D.L. Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology 2001, 156:194-215.
36. Yu C., Gupta J., Chen J.F., Yin H.H. Genetic deletion of A2A adenosine receptors in the striatum selectively impairs habit formation. Journal of Neuroscience 2009, 29:15100-15103.
37. Bleickardt C.J., Lashomb A.L., Merkel C.E., Hodgson R.A. Adenosine A(2A) receptor antagonists do not disrupt rodent prepulse inhibition: an improved side effect profile in the treatment of parkinson's disease. Parkinson Disease 2012, 2012:591094.
38. Hauber W., Koch M. Adenosine A2a receptors in the nucleus accumbens modulate prepulse inhibition of the startle response. Neuroreport 1997, 8:1515-1518.
39. Nagel J., Schladebach H., Koch M., Schwienbacher I., Müller C.E., Hauber W. Effects of an adenosine A2A receptor blockade in the nucleus accumbens on locomotion, feeding, and prepulse inhibition in rats. Synapse 2003, 49:279-286.
40. Sills T.L., Azampanah A., Fletcher P.J. The adenosine A2A agonist CGS 21680 reverses the reduction in prepulse inhibition of the acoustic startle response induced by phencyclidine, but not by apomorphine and amphetamine. Psychopharmacology 2001, 156:187-193.
41. Zerucha T., Stuhmer T., Hatch G., Park B.K., Long Q., Yu G., et al. A highly conserved enhancer in the Dlx5/Dlx6 intergenic region is the site of cross-regulatory interactions between Dlx genes in the embryonic forebrain. Journal of Neuroscience 2000, 20:709-721.
42. Wei C.J., Singer P., Coelho J., Boison D., Feldon J., Yee B.K., et al. Selective inactivation of adenosine A(2A) receptors in striatal neurons enhances working memory and reversal learning. Learning and Memory 2011, 18:459-474.
43. Meyer U., Chang D.L., Feldon J., Yee B.K. Expression of the CS- and US-pre-exposure effects in the conditioned taste aversion paradigm and their abolition following systemic amphetamine treatment in C57BL6/J mice. Neuropsychopharmacology 2004, 29:2140-2148.
44. Yee B.K., Balic E., Singer P., Schwerdel C., Grampp T., Gabernet L., et al. Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile. Journal of Neuroscience 2006, 26:3169-3181.
45. Yee B.K., Chang T., Pietropaolo S., Feldon J. The expression of prepulse inhibition of the acoustic startle reflex as a function of three pulse stimulus intensities, three prepulse stimulus intensities, and three levels of startle responsiveness in C57BL6/J mice. Behavioural Brain Research 2005, 163:265-276.
46. Yee B.K., Feldon J. Distinct forms of prepulse inhibition disruption distinguishable by the associated changes in prepulse-elicited reaction. Behavioural Brain Research 2009, 204:387-395.
47. Csomor P.A., Stadler R.R., Feldon J., Yee B.K., Geyer M.A., Vollenweider F.X. Haloperidol differentially modulates prepulse inhibition and p50 suppression in healthy humans stratified for low and high gating levels. Neuropsychopharmacology 2008, 33:497-512.
48. de Aguiar M.J., de Aguiar C.R., Guedes R.C. Caffeine/nutrition interaction in the rat brain: Influence on latent inhibition and cortical spreading depression. European Journal of Pharmacology 2011, 650:268-274.
49. Bakshi V.P., Geyer M.A., Taaid N., Swerdlow N.R. A comparison of the effects of amphetamine, strychnine and caffeine on prepulse inhibition and latent inhibition. Behavioural Pharmacology 1995, 6:801-809.
50. Schiller D., Weiner I. Basolateral amygdala lesions in the rat produce an abnormally persistent latent inhibition with weak preexposure but not with context shift. Behavioural Brain Research 2005, 163:115-121.
51. Martin G.E., Rossi D.J., Jarvis M.F. Adenosine agonists reduce conditioned avoidance responding in the rat. Pharmacology Biochemistry and Behavior 1993, 45:951-958.
52. Singer P., McGarrity S., Shen H.Y., Boison D., Yee B.K. Working memory and the homeostatic control of brain adenosine by adenosine kinase. Neuroscience 2012, 213:81-92.
53. Wang J.H., Short J., Ledent C., Lawrence A.J., Van Den Buuse M. Reduced startle habituation and prepulse inhibition in mice lacking the adenosine A2A receptor. Behavioural Brain Research 2003, 143:201-207.
54. Wardas J., Konieczny J., Pietraszek M. Influence of CGS 21680, a selective adenosine A(2A) agonist, on the phencyclidine-induced sensorimotor gating deficit and motor behaviour in rats. Psychopharmacology 2003, 168:299-306.
55. Heffner T.G., Wiley J.N., Williams A.E., Bruns R.E., Coughenour L.L., Downs D.A. Comparison of the behavioural effects of adenosine agonists and dopamine antagonists in mice. Psychopharmacology 1989, 98:31-37.
56. Kafka S.H., Corbett R. Selective adenosine A2A receptor/dopamine D2 receptor interactions in animal models of schizophrenia. European Journal of Pharmacology 1996, 295:147-154.
57. Receptor Coyle J.T.N.M.D.A, Schizophrenia A brief history. Schizophrenia Bulletin 2012, 38:920-926.
58. Javitt D.C. Twenty-five years of glutamate in schizophrenia: are we there yet?. Schizophrenia Bulletin 2012, 38:911-913.
59. Shen H.Y., Chen J.F. Adenosine A2A receptors in psychopharmacology: modulators of behavior, mood, and cognition. Current Neuropharmacology 2009, 7195-7206.
60. Ferré S., Quiroz C., Orru M., Guitart X., Gulyani S., Allen R., et al. Role of Striatal A2A Receptor Subpopulations in Neurological Disorders. Adenosine. A Key Link between Metabolism and Brain Activity 2013, 179-197. Springer, New York. S. Masino, D. Boison (Eds.).
61. Berrendero F., CastañéA.Ledent C., Parmentier M., Maldonado R., Valverde O. Increase of morphine withdrawal in mice lacking A2a receptors and no changes in CB1/A2a double knockout mice. European Journal of Neuroscience 2003, 17:315-324.
62. Ledent C., Vaugeois J.M., Schiffmann S.N., Pedrazzini T., El Yacoubi M., Vanderhaeghen J.J., et al. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2A receptor. Nature 1997, 388:674-678.
63. Jacobson K.A., von Lubitz D.K., Daly J.W., Fredholm B.B. Adenosine receptor ligands: differences with acute versus chronic treatment. Trends in Pharmacological Sciences 1996, 17:108-113.
64. Nikodijević O., Jacobson K.A., Daly J.W. Locomotor activity in mice during chronic treatment with caffeine and withdrawal. Pharmacology Biochemistry and Behavior 1993, 44:199-216.
65. Ferré S., Karcz-Kubicha M., Hope B.T., Popoli P., Burgueno J., Gutierrez M.A., et al. Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:11940-11945.
66. Gerevich Z., Wirkner K., Illes P. Adenosine A2A receptors inhibit the N-methyl-d-aspartate component of excitatory synaptic currents in rat striatal neurons. European Journal of Pharmacology 2002, 451:161-164.
67. Kachroo A., Orlando L.R., Grandy D.K., Chen J.F., Young A.B., Schwarzschild M.A. Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. Journal of Neuroscience 2005, 25:10414-10419.
68. Norenberg W., Wirkner K., Assmann H., Richter M., Illes P. Adenosine A2A receptors inhibit the conductance of NMDA receptor channels in rat neostriatal neurons. Amino Acids 1998, 14:33-39.
69. Deckert J., Nöthen M.M., Bryant S.P., Schuffenhauer S., Schofield P.R., Spurr N.K., et al. Mapping of the human adenosine A2a receptor gene: relationship to potential schizophrenia loci on chromosome 22q and exclusion from the CATCH 22 region. Human Genetics 1997, 99:326-328.
70. Hong C.J., Liu H.C., Liu T.Y., Liao D.L., Tsai S.J. Association studies of the adenosine A2a receptor (1976T>C) genetic polymorphism in Parkinson's disease and schizophrenia. Journal of Neural Transmission 2005, 112:1503-1510.
71. Luu S.U., Liao H.M., Hung T.W., Liu B.Y., Cheng M.C., Liao D.L., et al. Mutation analysis of adenosine A2a receptor gene and interaction study with dopamine D2 receptor gene in schizophrenia. Psychiatric Genetics 2008, 18:43.
72. Shen H.Y., Singer P., Lytle N., Wei C.J., Lan J.Q., Williams-Karnesky R.L., et al. Adenosine augmentation ameliorates psychotic and cognitive endophenotypes of schizophrenia. Journal of Clinical Investigation 2012, 122:2567-2577.